Syros Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Revenue
Operating expenses:
Research and development
General and administrative
Transaction related expenses
Restructuring (Note 14)
Total operating expenses
Loss from operations
Other income, net
Interest income
Interest expense
Change in fair value of warrant liability
Change in fair value of warrant liabilities
Net loss applicable to common stockholders
Net loss per share applicable to common stockholders - basic and diluted
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted
Net loss per share applicable to common stockholders - basic
Net loss per share applicable to common stockholders - diluted
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted

Comments